Nicolas Gazeau

Lille, 59000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.

Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.

Journal: Bone marrow transplantation

Published: April 21, 2025

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

Journal: Leukemia

Published: January 04, 2025

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.

Journal: Blood advances

Published: December 12, 2023

Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.

Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.

Journal: Haematologica

Published: August 08, 2023

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.

Journal: Blood advances

Published: July 22, 2023

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.

Journal: Transplantation and cellular therapy

Published: March 20, 2023

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.

Journal: British journal of haematology

Published: December 14, 2022

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.

Journal: Blood

Published: October 19, 2021

Effective anti-BCMA retreatment in multiple myeloma.

Effective anti-BCMA retreatment in multiple myeloma.

Journal: Blood advances

Published: January 04, 2021

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.

Journal: Leukemia

Published: November 04, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026